The system offers long-term monitoring for arrhythmias associated with conditions such as AFib, cryptogenic stroke and syncope.
Insertable cardiac monitors are a competitive space. Abbott won FDA clearance in May for its Assert-IQ ICM, while Medtronic continues to release positive data around its Linq monitors.
Boston Scientific designed LUX-Dx II+ with dual-stage algorithms to detect and verify potential arrhythmias before alerting clinicians. This provides actionable data for clinical decision-making when the clinicians receive an eventual alert.
LUX-Dx II+ also features remote programming capabilities. These allow physicians and care teams to adjust event detection settings and record symptoms without an in-patient appointment.
Boston Scientific said the system’s dual-stage algorithms can identify AFib, atrial and ventricular tachycardia, bradycardia and rhythm pause episodes. The algorithms feature a new premature ventricular contraction (PVC) burden, too. This allows the device to detect arrhythmias each time established thresholds or parameters are exceeded.
Additional levels of verification filters are then applied, including additional options for nighttime programming. Specific to bradycardia and pause episodes, the nighttime programming helps reject positive detections and irrelevant episodes. Patients can also download an app option for more convenient and seamless remote monitoring.
“The LUX-Dx II+ ICM System builds on a strong foundation of cardiac diagnostic technologies at Boston Scientific to provide care teams with the necessary data for critical decision making,” said Scott Olson, SVP and president, Cardiac Rhythm Management and Diagnostics, Boston Scientific. “With enhanced and new diagnostic algorithms, physicians will receive timely, accurate and actionable insights to help them make clinically meaningful decisions.”
